Database studies in asthma pharmacoeconomics: uses, limitations and quality markers

Author： Thomas Mike Cleland Jennifer Price David

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.3, 2003-03, pp. : 351-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomics of asthma treatment

By Cleland Jennifer Thomas Mike Price David

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 3, 2003-03 ,pp. : 311-318

Informa Healthcare

Access to resources Recommend Favorite

Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin

By Jones Terry E Smith Brian J Polasek Jonathen F

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 9, 2004-09 ,pp. : 1887-1897

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel in Non-Small Cell Lung Cancer: Impact on Quality of Life and Pharmacoeconomics

By Horn Leora Visbal Antonio Leighl Natasha B.

Drugs & Aging, Vol. 24, Iss. 5, 2007-01 ,pp. : 411-428

Adis International

Access to resources Recommend Favorite

Biological Markers in Older People at Risk of Mobility Limitations

Current Pharmaceutical Design, Vol. 20, Iss. 19, 2014-05 ,pp. : 3222-3244

Bentham Science Publishers

Access to resources Recommend Favorite

Asthma and quality of life

Inpharma, Vol. 1, Iss. 1311, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite